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Background. The prevalence and characteristics of persons with newly diagnosed human immunodeﬁciency virus
(HIV) infections with or without evidence of mutations associated with drug resistance have not been well described.
Methods. Drug-naive persons in whom HIV had been diagnosed during the previous 12 months and who did
not have acquired immune deﬁciency syndrome were sequentially enrolled from 39 clinics and testing sites in 10 US
cities during 1997–2001. Genotyping was conducted from HIV-ampliﬁcation products, by automated sequencing.
For specimens identiﬁed as having mutations previously associated with reduced antiretroviral-drug susceptibility,
phenotypic testing was performed.
Results. Of 1311 eligible participants, 1082 (83%) were enrolled and successfully tested; 8.3% had reverse
transcriptase or major protease mutations associated with reduced antiretroviral-drug susceptibility. The prevalence
of these mutations was 11.6% among men who had sex with men but was only 6.1% and 4.7% among women and
heterosexual men, respectively. The prevalencewas 5.4%and7.9%amongAfricanAmericanandHispanicparticipants,
respectively, and was 13.0% among whites. Among persons whose sexual partners reportedly took antiretroviral
medications, the prevalence was 15.2%.
Conclusions. Depending on the characteristics of the patients tested, HIV-genotype testing prior to the initiation
of therapy would identify a substantial number of infected persons with mutations associated with reduced antiret-
roviral-drug susceptibility.
Antiretroviral-drug resistance is an important cause of
treatment failure in persons infected with HIV-1 and has
been associated with increased mortality[1–4].Although
thetransmissionofdrug-resistantstrainsofHIVhasbeen
well documented [5], the prevalence and characteristics
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of persons with or without mutations associated with
drug resistance are less clear. A number of studies have
examined the prevalence of mutations associated with
resistance in small samples of recently or acutelyinfected
persons, mostly white men who have sex with men
(MSM) [6–13]. Fewer studies have assessed the preva-
lence of mutations in drug-naive persons with newly
diagnosed infections whose infections are, for the most
part, of unknown duration; these persons are more typ-
ical of HIV-infected patients presenting for initial eval-
uation and treatment. In addition, few studies have been
sufﬁciently large and representative of newly diagnosed
HIV to describe the characteristics of persons infected
with drug-resistant strains of HIV.
A concern with testing chronically infected patients
is that, even if drug-resistant mutations are initially
present, in the absence of drug selection pressures,Epidemiology of Antiretroviral Drug Resistance • JID 2004:189 (15 June) • 2175
drug-resistant mutations may become undetectable if the in-
fecting strains revert to wild type or become overgrown by
ﬁtter wild-type viruses; persisting as archived viruses or as mi-
nority species, they may not be detectable by current assays
[14], even though they may become problematic with the in-
troduction of therapy and selective pressures on the predom-
inant wild-type strains. Consequently, resistance testing prior
to initiationof antiretroviraltherapyinpersonswithestablished
HIV infection, although recommended by some when duration
of infection or regional prevalence can be established [15], has
not been widely recommended in the United States [16].
To describe the prevalence and characteristicsofpersonswith
mutations associated with reduced drug susceptibility, we sys-
tematically enrolled, in multiple venues across the United
States, drug-naive persons in whom HIV infection had been
recently diagnosed. As a better understanding of patterns of
antiretroviral-drug resistance in persons presenting for care
emerges, this kind of information may help to guide recom-
mendations for baseline resistance testing and, possibly, the
selection of initial antiretroviral regimens.
PATIENTS AND METHODS
Patients. HIV-1–infectedpersonsinwhomtheconditionhad
been diagnosed during the previous 12 months were enrolled
consecutively from 39 selected HIVcareclinics,HIVcounseling
and testing sites, and other clinical settings in 10 US cities
during 1997–2001. Eligibility criteria included age 18 years,
antiretroviral-drug–naive status according to medical chart re-
view (if a chart was available) and personal interview, and no
history of AIDS-deﬁning conditions (including a CD4
+ T cell
count !200 cells/mm
3). After informed consent was obtained,
demographic, risk-behavior, and clinical information was ob-
tained from medical charts, if available, and from standardized
interviews. Blood specimens were obtained from each con-
senting participant. The study wasapprovedbytheinstitutional
review board at the Centers for Disease Control and Prevention
and by the local human-subject review boards afﬁliated with
the clinics or other sites where participants were enrolled.
Resistance testing. Reverse transcriptase (RT) and protease
genotyping was conducted on the basis of HIV-ampliﬁcation
products, by automated sequencing (Applied Biosystems) at the
Centers for Disease Control and Prevention (165 specimens
[GenBank accession numbers AY471869–AY472017]), ViroLogic
(249 specimens), and Virco (668 specimens) laboratories. The
mutations included in the analysis that were identiﬁed by se-
quencing at the ViroLogic and Virco laboratories were based
on the reports of mutations provided by those laboratories.
The analysis considered (1) RT-gene mutations that have been
associated with reduced susceptibility to RT inhibitors and (2)
major protease-gene mutations that have been associated with
reduced susceptibility to protease inhibitors, as reported by the
InternationalAIDSSociety–USAinJune2002[17]:RT—M41L,
A62V, K65R, D67N, T69D, 69 insert, K70R, L74V, V75I, V75T,
V75M, V75S, V75A, F77L, L100I, K103N, V106A, V108I,
Y115F, F116Y, Q151M, Y181C, Y181I , M184V, M184I, Y188C,
Y188L, Y188H, Y188C, G190A, G190S, L210W, T215Y, T215F,
K219Q, K219E, P225H, M230L, and P236L; protease—D30N,
M46I, M46L, G48V, I50V, V82A, V82S, V82F, V82T, I84V, and
L90M. In addition, all RT mutations at codon 215 that were
different from wild-type T215 were included [17, 18], as were
the T69A/N/S mutations.
Plasma specimens having an RT mutation or a major protease
mutation associated with reduced drug susceptibility were test-
ed phenotypically at the ViroLogic (29 specimens) or Virco (50
specimens) laboratories, by recombinant-virus assays [19, 20].
The following antiretroviral drugs approved by the Food and
Drug Administration were tested: zidovudine, didanosine, zal-
citabine, stavudine, lamivudine,abacavir,nevirapine,delavirdine,
efavirenz, saquinavir, ritonavir, indinavir, and nelﬁnavir. Fold
changes in the IC50 of the patient’s virus, relative to that of the
reference wild-type viruses, were used to categorize phenotypic
results as either sensitive or resistant according to cutoff values
established by the manufacturers [21, 22].
Additional HIV antibody testing for recency of infection.
All specimens for which informed consent was provided were
also tested by a modiﬁed version of the HIV-1 enzyme im-
munoassay (Vironostika HIV-1 EIA; bioMerieux) [23, 24].This
assay is less sensitive than the standard HIV-1 enzyme im-
munoassay—it becomes reactive ∼170 days after the standard
EIA becomes positive; thus, HIV-infected persons in whom the
virus does not react by the modiﬁed EIA are considered to have
been infected during the previous 4–6 months (“recent infec-
tion”). All testing by this assay was conducted at 1 laboratory
(San Francisco Department of Public Health), where assay per-
formance was monitored [25].
Statistical analysis. We used the Mantel Haenszel x
2 test
and, where appropriate, Fisher’s exact test to compare pro-
portions of different HIV-infected populations with mutations
associated with reduced drug susceptibility.Becauseofthesmall
numbers of persons enrolled in 1997 and 2001, trends were
analyzed for 1998–2000 only. Only clinics submitting data for
all 3 of these years were included in analyses of trends. All
statistical analyses were performed by use of SAS version 6.12
(SAS Institute).
RESULTS
Of 1311 persons eligible for enrollment in this study, 1104
(84%) agreed to participate, and viral sequences from 1082
(83%) were successfully ampliﬁed; the analysisfocusedonthese
1082 HIV-1–infected individuals. Table 1 summarizes demo-2176 • JID 2004:189 (15 June) • Weinstock et al.
Table 1. Characteristics of total study population and of per-
sons with mutations associated with reduced susceptibility to
reverse-transcriptase (RT) or protease inhibitors, in 10 US cities
during 1997–2001.
Characteristic
No. (%) of persons
P
a Total
With RT or major
protease mutation
Total 1082 90 (8.3)
Age group .07
!25 135 14 (10)
25–34 453 41 (9.1)
35–44 323 27 (8.4)
144 171 8 (4.7)
Sex .11
Male 802 73 (9.1)
Female 280 17 (6.1)
Race/ethnicity
b .002
African American 498 27 (5.4)
Hispanic 240 19 (7.9)
White 292 38 (13)
Other 21 3 (9.5)
Site type .32
HIV care clinics 668 52 (8.6)
HIV testing site 372 32 (7.8)
Other clinical facility 42 6 (14)
City .22
San Francisco 75 9 (12)
San Diego 39 7 (18)
Denver 179 17 (9.5)
Detroit/Grand Rapids 46 4 (8.7)
Houston 187 9 (4.8)
New York 127 12 (9.5)
Newark 170 11 (6.5)
New Orleans 137 10 (7.3)
Miami 122 11 (9.0)
HIV risk behavior .001
Male-to-male sex 482 56 (12)
Injection drug use
c 110 9 (8.2)
Heterosexual exposure
d 490 25 (5.1)
Recently infected .07
Yes 182 21 (12)
No 767 57 (7.4)
CD4 count .56
!350 cells 151 13 (8.6)
350 cells 389 36 (9.3)
Partner taking HIV medications !.001
Yes 171 26 (15)
No 736 45 (6.1)
a Based on x
2 test.
b Information about race/ethnicity was not known for 31 persons.
c Does not include individuals who also reported male-to-male sex.
d Does not include individuals who also reported male-to-male sex or in-
jection drug use.
graphic and clinical characteristics of the study population.
Most were male, and 46% were AfricanAmerican,whereas22%
were of Hispanic origin. Most participants were enrolled from
HIV care clinics. A substantial proportion of male participants,
60%, reported being MSM. A modiﬁed version of the HIV-1
enzyme immunoassay found 19% (182 of 949 persons who
provided informed consent for additional testing) to have been
recently infected with HIV.
Although the proportion of HIV-infected persons with mu-
tationsassociatedwithreducedantiretroviraldrugsusceptibility
did not vary signiﬁcantly by age group, city, site of enrollment,
CD4
+ T cell count, or recency of infection, persons with these
mutations were more likely to be white, to be MSM, and/or
to have a partner taking antiretroviral medications (table 1).
The overall prevalence of mutations associated with reduced
antiretroviral drug susceptibility was 8.3%; however, it was
6.1% and 4.7% in women and heterosexual men, respectively,
and was 12% in MSM. The prevalence was 5.4% and 7.9% in
African American and Hispanic persons, respectively, and was
13% in whites. Figure 1 shows that, for both sexual orientations
and for both sexes, whites had the highest prevalence of these
mutations; white MSM had the highest overallprevalence(14%),
and Hispanic and African American heterosexual men and Af-
rican American women had the lowest prevalences (4.3%, 4.6%,
and 4.9%, respectively).
The prevalence of these mutations also varied according to
the drug class with which they are associated (table 2). Of the
90 persons with RT mutations or major protease mutations, 69
(77%) had RT mutations associated with reduced susceptibility
to the nucleoside reverse-transcriptase inhibitors (NRTIs); 40 of
these 69 persons had 1, 24 had 2, 3 had 3, and 2 persons had
4.ThemostcommonlyobservedNRTIresistance–associatedmu-
tations were M41L (19 persons), K70R (9 persons), M184V (9
persons), and D67N (7 persons). There were 4 persons with
T215Y or T215F mutations; 27 other persons had T215D/S/C/
E/I mutations, and 15 persons had T69D/N/S/A mutations.
When persons with T215D/S/C/E/I or T69N/S/A mutationswere
excluded, 69 (6.4%) of 1082 persons had resistance-associated
mutations, and 48 (4.4%) of 1082 had NRTI-associated
mutations.
Nonnucleoside-associated reverse-transcriptase mutations
were found in 18 (1.7%) of the 1082 study participants, and
major protease mutations were found in 21 (1.9%). The most
commonly observed nonnucleoside-associated mutation was
K103N (10 persons), and the most commonly observed major
protease mutations were L90M (10 persons) and M46I (8 per-
sons). Only 14 persons (1.3%) had mutations associated with
reduced susceptibility to antiretroviral medications in 2d r u g
classes; these 14 persons, 10 of whom were MSM, were enrolled
from 7 of the 10 study cities.
The prevalence of mutations associated with reduced anti-
retroviral-drug susceptibility was higher in the 182 persons
found to have been recently infected with HIV (12%) than in
the rest of the study population (7.4%); however,thisdifference
was not statistically signiﬁcant. The prevalence of such muta-
tions in MSM who had been recently infected with HIV wasEpidemiology of Antiretroviral Drug Resistance • JID 2004:189 (15 June) • 2177
Figure 1. Prevalence of reverse-transcriptase and major protease mutations associated with reduced antiretroviral-drug susceptibility, by race/
ethnicity and sexual orientation, in 1082 HIV-infected persons in 10 US cities during 1997–2001.
Table 2. Prevalence of mutations associated with reduced drug susceptibility, by drug class
and phenotypic conﬁrmation of genotypic ﬁndings, in 1082 HIV-1–infected persons in 10 US cities
during 1997–2001.
Drug class
No. of persons (% of study
population [N p 1082])
with associated mutation
a
No. (%) of persons
with reduced susceptibility
b
RT inhibitor or major protease inhibitor 90 (8.3) 31/79 (39)
Nucleoside RT inhibitor 69 (6.4) 13/58 (22)
Nonnucleoside RT inhibitor 18 (1.7) 14/18 (78)
Major protease inhibitor 21 (1.9) 10/20 (50)
2 drug classes 14 (1.3) 12/14 (86)
NOTE. RT, reverse transcriptase.
a Mutation associated with reduced drug susceptibility [17].
b The denominator reﬂects the number of persons with resistance associated mutations who were successfully
phenotyped; 8 specimens with codon changes at 69 were not submitted for phenotypic testing; 3 specimens could
not be successfully tested. Cutoff values for reduced sensitivity were deﬁned by the manufacturers: Virologic, Inc.—
4.5-fold for abacavir, 1.7-foldfor didanosineandstavudine,and2.5-foldfortheothers[21];Virco—4.0-foldforzidovudine
and nelﬁnavir, 4.5-fold for lamivudine, 3.5-fold for didanosine, zalcitabine, and ritonavir, 3.0-fold for stavudine,abacavir,
and indinavir, 8-fold for nevirapine, 10-fold for delaviridine, 6-fold for efavirenz, and 2.5-fold for saquinavir [22].
15%, whereas that in MSM whose infections were not recent
was 11%; this difference too was not statistically signiﬁcant.
Similarly, recently infected heterosexual men had a higher, but
not statistically different, prevalence of mutations than did het-
erosexual men whose infections were not recent (7.3%, com-
pared to 4.4%); also, the prevalence of such mutations in
women whose infections were recent was not statistically dif-
ferent from that in women whose infections were not recent
(3.3%, compared to 5.8%), and within each racial or ethnic
group, the prevalence in persons whose infections were recent
was not different than that in persons whose infections were
not recent.
Some mutations were more likely to be found in persons
with recent infections. In persons in whom recency of infection
was tested by the modiﬁed HIV-1 EIA, 6 of 8 with the M184V
mutation and 5 of 8 with the K103N mutation were found to
have been recently infected. In contrast, only 4 of 27 persons
with HIV containing changes at codon 215, 2 of 13 persons
with changes at codon 69, 5 of 17 persons with the M41L
mutation, and 3 of 10 persons with the L90M mutation were
found to have been recently infected.
The prevalence of mutations in recently infected persons
varied by year (7.1% in 1998, 14% in 1999, and 8.9% in 2000);
these differences were not statistically signiﬁcant. This preva-
lence increased over time in persons not recently infected,from
3.2% in 1998 to 9.0% in 1999 to 12% in 2000 ( , x
2 P p .004
for trend).
Of the 79 persons with an RT mutation or major protease
mutation who were successfully tested phenotypically, only 31
(39%) showed phenotypic evidence of decreased susceptibility
to the drugs with which their mutations have been associated
(table 2). This ﬁnding varied by drug class. Only 13 (22%) of
the 58 persons where viruses had NRTI mutations were found
to have phenotypic evidence of resistance. In this group, the
presence of a large number of viruses, with T215D/S/C/E/I
mutations, that had wild-type susceptibility to zidovudinecon-2178 • JID 2004:189 (15 June) • Weinstock et al.
tributed to the low proportion with decreased susceptibility.
Additionally, of the 19 persons with virus having the M41L
mutation, only 3 showed evidence of decreased susceptibility
to zidovudine, and 2 of those persons had virus with the T215Y
mutation as well. On the other hand, 6 of 8 persons with vi-
rus carrying the M184V mutation had phenotypic evidence
of resistance to lamivudine, and all 10 persons with virus with
the K103N mutation had phenotypic evidence of resistance to
non-NRTIs.
Persons with mutations associated with reduced antiretroviral
drug susceptibility who also had phenotypic evidence of resis-
tancewere,likeallpersonswiththesemutations,statisticallymore
likely to be white, to be MSM, and/or to report a partner taking
antiretroviral medications than were persons with virus without
these mutations. They were also more likely to have beenrecently
infected (50%, compared to 18%; ). P ! .001
DISCUSSION
In patients infected with HIV, the ﬁrst therapeutic regimen is
the most important one for producing a maximal and durable
virologic response[16]. Optimizingthatinitialregimenisthere-
fore critical, and, for this reason, testing for the presence of
drug-resistant strains of HIV prior to the initiation of therapy
may be beneﬁcial to the patient and cost effective [26]. The
ﬁndings of the present study of drug-naive persons with newly
diagnosed infections suggest that such a strategy of resistance
testing would identify a substantial number of persons with
HIV containing mutations associated with reduced antiretro-
viral-drug susceptibility.
These ﬁndings document that many mutations remain de-
tectable 4–6 months after infection and support previous stud-
ies’ observation, in a few patients, that transmitted drug-re-
sistant virus may persist for months or years [27, 28]. The
continued presence of these mutations and the ability to detect
them have important implications both for resistance testing
in drug-naive patients with established infection and for the
conduction of surveillance of mutations associated with re-
duced antiretroviral-drug susceptibility in this population.
We did ﬁnd that the prevalence of mutations associated with
reduced antiretroviral-drug susceptibility in persons whose in-
fections were recent is higher than that in persons whose in-
fections were not. Although this difference is not statistically
signiﬁcant when all mutations are considered, some mutations,
particularly those that could be conﬁrmed phenotypically, are
morelikelyto befoundinrecentlyinfectedpersons.Theshorter
persistence of some mutations may be explained by decreased
viral ﬁtness and, thus, a faster rate of reversion to a more
replication-competent variant [29, 30].
Of persons with detectable viral mutations identiﬁed in the
present study, only 39% had phenotypic evidence of resistance.
The inclusion of mutations that indicate prior drug exposure
but do not actually confer drug resistance may account, in part,
for the lower prevalence of phenotypic resistance observed in
this and other studies [6, 7]. Although the presence of genotypic
or phenotypic markers of resistance in recently infected persons
has generally been linked to reduced virologic responses to anti-
retroviral therapy [6, 7], the clinical implications of many resis-
tance-associated mutations are not fully deﬁned. We therefore
caution against using these prevalence data to imply rates of
virologic failures that would occur in patients initiating therapy;
however, close monitoring of treatment responses in patients
infected with viruses with these mutations may be warranted.
The largest proportion (41%) of persons with NRTI-associ-
ated mutations had mutations at codon 215, such as T215D/
S/C/E/I, that differ from either wild type or the zidovudine/
stavudine–selected T215Y/F. These mutations are known to be
revertants of T215Y, and, although they are phenotypicallysen-
sitive to zidovudine, the mutant viruses can acquire T215Y in
vitro more rapidly than can wild-type HIV-1, likely reﬂecting
the fact that only 1 nucleotide change is necessary for evolution
to T215Y [17]. Preliminary data suggest that patientswiththese
mutations, after initiating therapy, do have an increased risk
of virologic failure [31].
The prevalence of mutations associated with reduced anti-
retroviral-drug susceptibility varies depending ontheparticular
population being tested. We found that the prevalence of mu-
tations associated with reduced drug susceptibility was higher
in whites and MSM than in other populations. We also found
that the prevalence of these mutations was higher in persons
reporting partners who took antiretroviral medications, sug-
gesting that these viruses may have been transmitted direct-
ly from treated persons. The higher prevalence in whites and
MSM may reﬂect better access to health care and treatment in
these populations [32, 33]. Our results help to explain the
prevalence of mutations found by others, whose study popu-
lations consisted mostly of recently or acutely infected white
MSM [6, 7, 13].
Although we did not observe evidence of an increasing prev-
alence of mutations associated with reduced drugsusceptibility,
over time, in recently infected individuals, the number of re-
cently infected individuals in our study is small. We did see an
increasingprevalenceinpersonswhowerenotrecentlyinfected;
however, these trend data should be regarded with some cau-
tion, because they are limited to just 3 years.
We did not study a random sample of HIV-infected indi-
viduals; nevertheless, to date, this is the largest, most diverse
population in the United States that has been studied for an-
tiretroviral-drug resistance and, with the exception of the over-
sampling of Hispanics (only 11.3% of persons reported with
HIV nationally are Hispanic, compared to 22% in the present
study), our study well reﬂects the demographic characteristicsEpidemiology of Antiretroviral Drug Resistance • JID 2004:189 (15 June) • 2179
of persons reported with HIV as well as the proportionofMSM
[34]. It should be noted that the persons in this study had CD4
T cell counts 200 cells/mm
3; according to current guidelines,
many may not have had indications for starting antiretroviral
therapy.
Although the epidemiology of antiretroviral-drug resistance
may reﬂect the HIV-infected populations that are seeking and
receiving antiretroviral therapy, it also reﬂects, as others have
noticed, the health care system’s failures to prevent HIV trans-
mission from these treated populations [6]. Recently reported
increases in risky sexual behaviors, as evidenced by increases
in sexually transmitted diseases in MSM with high rates of HIV
coinfection [35–37], suggest that HIV infection rates may also
be increasing in this group. Health care providers who are
caring for HIV-infected patients can play a prominent role in
helping to prevent the further transmission of HIV, including
drug-resistant virus.
In summary, HIV genotypic testing prior to the initiation of
therapy in patients with newly diagnosed HIV infections and
without AIDS would identify a substantial number of persons
with virus with mutations associated with reduced antiretro-
viral-drug susceptibility. The prevalence of thesemutationsvar-
ies depending on the characteristics of the patients tested and
thedurationof theirinfections.Continuedsurveillanceforanti-
retroviral-drug resistance in sufﬁciently large, representative
samples of persons with newly diagnosed HIV will be necessary
to monitor changes, over time, in the prevalence and the pop-
ulations affected.
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